Drug Profile
BC 007
Alternative Names: BC-007Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator Berlin Cures
- Class Antivirals; Cardiovascular therapies; Heart failure therapies; Nucleotide aptamers; Peptide aptamers; Proteins
- Mechanism of Action Autoantibody inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic heart failure; Dilated cardiomyopathy; Post acute COVID 19 syndrome
- No development reported Chronic fatigue syndrome
Most Recent Events
- 16 Jun 2023 Phase-II clinical trials in Post-acute-COVID-19-syndrome in Austria (IV) (NCT05911009)
- 16 May 2023 Universitätsklinikum Erlangen initiates a phase II trial for Post-acute-COVID-19-syndrome in Germany (IV, Infusion) (EudraCT2022-001781-35)
- 02 May 2023 Phase-II clinical trials in Post-acute-COVID-19-syndrome in Finland (IV) (EudraCT2022-003452-14)